Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10458888 | 0.98 | ALDH1A1 (0.58) | ALDH1A1HTTLMNACA1CA2 | |
| SCHEMBL4614428 | 0.80 | ALDH1A1 (0.67) | ALDH1A1HTTLMNACA1CA2 | |
| SCHEMBL21118113 | 0.77 | ALDH1A1 (0.62) | ALDH1A1HTTLMNACA1CA2 | |
| SCHEMBL5114807 | 0.75 | ALDH1A1 (0.60) | ALDH1A1HTTLMNACA1CA2 | |
| SCHEMBL4614425 | 0.75 | ALDH1A1 (0.60) | ALDH1A1HTTLMNACA1CA2 | |
| SCHEMBL7355629 | 0.75 | ALDH1A1 (0.67) | ALDH1A1HTTLMNACA1CA2 | |
| SCHEMBL3759352 | 0.75 | ALDH1A1 (0.60) | ALDH1A1HTTLMNACA1CA2 | |
| SCHEMBL11033708 | 0.75 | ALDH1A1 (1.00) | ALDH1A1HTTLMNACA1CA2 | |
| SCHEMBL5758981 | 0.75 | ALDH1A1 (0.60) | ALDH1A1HTTLMNACA1CA2 | |
| SCHEMBL13715429 | 0.75 | ALDH1A1 (0.60) | ALDH1A1HTTLMNACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967216-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-11-22 | — | — | US | claimed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |
| EP-1278739-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | claimed |
| WO-2001085714-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | ASTRAZENECA AB (SE) | 2001-11-15 | — | — | WO | claimed |
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| US-7332492-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-6967216-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-11-22 | — | — | US | disclosed |
| US-20050209233-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-09-22 | — | — | US | disclosed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209233-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | NPY5R, NPY1R, NPY2R | ALDH1A1 3658/4885HTT 1327/4885LMNA 3803/4885 |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | NPY5R, NPY1R, NPY2R | ALDH1A1 3792/4885HTT 1462/4885LMNA 3935/4885 |
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | TGFBR1, TGFBR2, SMAD3 | ALDH1A1 163/4885HTT 4346/4885LMNA 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.